Historique
Rapport
Prescription drugs: OxyContin abuse and diversion and efforts to address the problem
(Abus et usage détourné d'OxyContin. Les efforts mis en place pour signaler le problème)
Auteur(s) :
United States General Accounting Office (GAO)
Année
2003
Page(s) :
63 p.
Langue(s) :
Anglais
Éditeur(s) :
Washington, DC : General Accounting Office (GAO)
, GAO-04-110
Domaine :
Autres substances / Other substances
Discipline :
EPI (Epidémiologie / Epidemiology)
Thésaurus mots-clés
ANALGESIQUES
;
OPIOIDES
;
MEDICAMENTS
;
MESUSAGE
;
AMM
;
REGLEMENTATION
;
SURVEILLANCE EPIDEMIOLOGIQUE
Thésaurus géographique
ETATS-UNIS
Note générale :
Washington, General Accounting Office, 2003, 63 p.
Résumé :
Amid heightened awareness that many patients with cancer and other chronic diseases suffer from undertreated pain, the Food and Drug Administration (FDA) approved Purdue Pharma's controlled-release pain reliever OxyContin in 1995. Sales grew rapidly, and by 2001 OxyContin had become the most prescribed brandname narcotic medication for treating moderate-to-severe pain. In early 2000, reports began to surface about abuse and diversion for illicit use of OxyContin, which contains the opioid oxycodone. GAO was asked to examine concerns about these issues. Specifically, GAO reviewed (1) how OxyContin was marketed and promoted, (2) what factors contributed to the abuse and diversion of OxyContin, and (3) what actions have been taken to address OxyContin abuse and diversion. (Author' s abstract)
Affiliation :
Etats-Unis. United States.